Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.6100
+0.0039 (0.64%)
At close: Dec 5, 2025, 4:00 PM EST
0.6000
-0.0100 (-1.64%)
After-hours: Dec 5, 2025, 7:55 PM EST
Scienture Holdings Revenue
Scienture Holdings had revenue of $590.05K in the quarter ending September 30, 2025, with 809.71% growth. This brings the company's revenue in the last twelve months to $653.39K, up 207.88% year-over-year. In the year 2024, Scienture Holdings had annual revenue of $136.64K, down -89.98%.
Revenue (ttm)
$653.39K
Revenue Growth
+207.88%
P/S Ratio
12.01
Revenue / Employee
$34,389
Employees
19
Market Cap
24.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | 1.06M | 354.61% |
| Dec 31, 2022 | 300.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNX News
- 4 days ago - SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 - GlobeNewsWire
- 23 days ago - SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans - GlobeNewsWire
- 6 weeks ago - SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium) - GlobeNewsWire
- 7 weeks ago - SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers - GlobeNewsWire
- 7 weeks ago - Wellgistics Health Announces Executive Management and Board Changes - Accesswire
- 2 months ago - SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market - GlobeNewsWire
- 4 months ago - Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock - GlobeNewsWire